[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-cough-cc\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-cough-cc":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,51,81,106,128,157,180,205],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100589926","phase-2-mechanisms-of-change-in-behavioral-cough-suppression-therapy-for-refractory-chronic-cough-100589926",false,"NCT06960759","Mechanisms of Change in Behavioral Cough Suppression Therapy for Refractory Chronic Cough","CoughLESS","INCLUSION CRITERIA\n\nTo be eligible to participate, participants must meet the following criteria:\n\n* 18 - 99 years of age\n* Diagnosis of refractory or unexplained chronic cough\n* Normal chest imaging (x-ray or CT scan) within past 2 years, without change in cough symptoms\n* If you a potential participant has asthma, the following criteria must be met:\n\n  * Asthma diagnosed by a pulmonary provider\n  * Documentation from a pulmonary provider that asthma is well-controlled\n  * Agree to carry prescribed rescue inhaler to each study visit\n  * Can tolerate, and agree to, avoid rescue inhaler use for 4 hours prior to each study visit. If rescue inhaler use is unavoidable within 4 hours of a study visit, agree to inform researchers in advance so that the session can be rescheduled.\n* Normal pulmonary function testing with spirometry (FEV1\u002FFVC of at least 70% if diagnosed with asthma) within 2 years (6 months for those with a diagnosis of asthma), without change in symptoms since (NOTE: spirometry is included as part of cough threshold testing and can serve as this criteria if the participant has not had spirometry within the designated time.)\n* Laryngoscopy or stroboscopy within 2 years without evidence of structural pathology and no change in vocal quality since exam\n* Proficient reader\u002Fspeaker of English\n* Willing to take a pregnancy test before enrollment (if applicable)\n* Willing to use contraception during the study (if applicable)\n* Access to reliable internet, working email address (for surveys) and a smart phone (for use with CoughMonitor Watch)\n* Demonstrates understanding in study procedures and risks in order to consent\n* Available, and willing, to comply to all study procedures and clinic visits.\n\nEXCLUSION CRITERIA\n\nAny of the following will be grounds for exclusion from the study:\n\n* Currently a smoker of any substance or has a positive history of smoking any substance within the last 6 months\n* Currently suffering from any signs of an upper respiratory infection (other than cough)\n* Hemoptysis (coughing up blood) within the last 6 months\n* Pulmonary diagnosis other than asthma\n* Asthma criteria - participant is deemed ineligible if screened for one or more of the following:\n\n  * Use of rescue inhaler in response to active asthma symptoms ≥ 2 times per week\n  * Respiratory related emergency department visit within the past 4 weeks\n  * Respiratory related ICU admission within the past 12 months\n  * Asthma exacerbation requiring systemic corticosteroid use within the past 4 weeks\n* Pregnant or trying to become pregnant\n* Any complaints or clinical symptoms of dysphagia\n* Live with someone with chronic cough or work with someone with chronic cough who is in close proximity (e.g., within 25 feet) on a daily or nearly daily basis\n* Known allergy to peppers\n* Currently receiving or has received BCS therapy for management of refractory chronic cough\n* Excluded concomitant medications:\n\n  * Inhaled pulmonary medications (inhaled corticosteroids, short-acting beta agonists, long-acting beta-agonist, short-acting muscarinic antagonists), unless prescribed for asthma by pulmonary provider: 30 days prior to Visit 1 through completion of study participation\n  * ACE inhibitor (benazepril, captopril, enalapril, fosiniopril, lisinopril, perindopril, quinapril, ramipril, trandolapril): 30 days prior to Visit 1 through completion of study participation.\n  * Narcotic antitussive (hydrocodone, oxycodone, morphine, codeine, tramadol): 7 days prior to Visit 1 through completion of study participation\n  * Non-narcotic antitussive (benzonatate\u002FTessalon, dextromethorphan\u002FDelsym, carbetapentane\u002FSolotuss): 7 days prior to Visit 1 through completion of study\n  * P2X3 receptor antagonist (gefapixant\u002FLyfnua): 14 days prior to Visit 1 through completion of study\n  * Any off-label prescription medication prescribed for cough (pregabalin\u002FLyrica, gabapentin\u002FNeurontin, amitriptyline\u002FElavil): 14 days prior to Visit 1 through completion of study \\*if a neuromodulator is prescribed for something other than cough, participant must be on a stable dose for a minimum of 7 days\n\nThe following additional exclusion criteria will apply to participants who will undergo fMRI:\n\n* Presence of metal implants, devices or fragments (e.g., shrapnel) in the body\n* Claustrophobia","ALL","18 Years","99 Years",{"count":20,"type":21},135,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This study is testing new ways to help people who have chronic cough that has not improved with typical treatments. One approach is called behavioral cough suppression (BCS) therapy, which teaches people techniques to stop themselves from coughing. Another approach uses a natural substance thought to help reduce the body's sensitivity to cough triggers.\n\nIn this study, we will test two treatments and include one no-treatment control group. The control group will undergo baseline testing, cough monitoring, and an fMRI brain scan and will be offered BCS at end of study participation.\n\nThe two treatments include:\n\n* BCS therapy with active inhaled treatment (BCS+active),\n* BCS therapy with inactive inhaled treatment (BCS+inactive),\n\nThe investigators will enroll 135 adults with refractory chronic cough (RCC). 100 participants who qualify and are willing and able to complete 14 study visits in the clinic and two online study visits will be randomly assigned to one of the two treatments. The no-treatment control group (n=35) will be recruited from adults with RCC who are willing to complete baseline testing and fMRI but are not able or willing to attend 14 study clinic visits. These participants will not be randomized.\n\nThe investigators want to find out how these treatments affect:\n\n* How sensitive someone is to things that make them cough,\n* How well they can hold back a cough when they try,\n* How their brain responds to things that cause an urge-to-cough,\n* And how much their coughing affects their quality of life.\n\nThe investigators believe both treatments will reduce sensitivity to cough stimulants, reduce cough severity, and improve quality of life, but BCS+active inhaled treatment will work better than BCS+inactive inhaled treatment.",[27,28,29],"Chronic Cough (CC)","Refractory Chronic Cough","Unexplained Chronic Cough",[31,32,33,34,35,36,37],"cough hypersensitivity syndrome","randomized control trial","neurogenic cough","refractory chronic cough","unexplained chronic cough","chronic cough","behavioral cough suppression therapy","NOT_YET_RECRUITING","2026-06-01",{"date":41,"type":42},"2026-06-03","ACTUAL",{"date":44,"type":21},"2026-06-29",{"date":46,"type":21},"2030-03-31",{"name":48,"class":49},"University of Montana","OTHER",3,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100582087","canadian-consortium-on-airway-mucus-occlusions-in-asthma-copd-and-chronic-cough-100582087","NCT06858748","Canadian Consortium on Airway Mucus Occlusions in Asthma, COPD and Chronic Cough","Canadian Consortium for Understanding the Role of Airway Mucus Occlusions in Asthma, COPD and Chronic Cough","CANMuc","Inclusion Criteria:\n\n* Males and females (≥18 years old)\n\nAsthma: Respiratory physician confirmed diagnosis of moderate-to-severe asthma and Historical objective evidence of asthma and\u002For specialist\u002Frespirologist confirmation (post-bronchodilator reversibility and\u002For methacholine bronchoprovocation test \\\u003C8 mg\u002FmL)\n\nCOPD: Respiratory physician confirmed diagnosis of COPD that is moderate-to-severe according to GOLD criteria (post-bronchodilator FEV1\u002FFVC\\\u003CLLN and FEV1\\\u003C 80%pred) and CAT score ≥10 or mMRC score ≥ 2\n\nChronic cough: Refractory Chronic Cough (RCC) and Unexplained Chronic Cough (UCC) lasting \\>1 year with Normal chest radiograph and no airflow obstruction (FEV1\u002FFVC \\>Lower Limit of Normal)\n\nHealthy participants: No history of respiratory disease or other pulmonary disorders and no use of inhaled medications or corticosteroids with normal spirometry and Modified Medical Research Council (mMRC) Dyspnea Scale =\\\u003C1\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding\n* Current smoker or \\>10 yr pack history or smoked within the last 6 months\n* Exacerbation within 4 weeks of recruitment\n* Preterm birth (≤36 weeks gestation) or perinatal complications\n* History of other pulmonary disorders\n* Specialist\u002FRespirologist suspects primary ciliary dyskinesia (PCD)\n* Current use of mucolytic medications\n* Memory, cognitive, or psychiatric limitations that may prevent optimal participation\n* Treatment with current biologic therapy: anti-IgE mAb within 130 days, anti-IL-4\u002F4R, IL-5\u002F5R, IL-13, or TSLP within 2 months or 5 half-lives whichever is longer prior to visit 1",true,{"count":61,"type":21},240,"OBSERVATIONAL","Chronic lung diseases affect one in five Canadians, causing symptoms such as cough, breathlessness, and wheeze. Despite advancements in medical care, these conditions not only impact individuals and their close circles but also present substantial clinical and economic challenges at a national level. This grant is dedicated to addressing three prevalent lung diseases: asthma, chronic obstructive pulmonary disease (COPD), and chronic cough. An alliance of clinicians, scientists, knowledge users, and patient partners from across Canada have come together to establish the Canadian Consortium for Understanding the Role of Airway Mucus Occlusions in Asthma, COPD, and Chronic Cough - \"CANMuc.\" Mucus plays a pivotal role in the symptoms and severity of lung diseases, but its clinical assessment has been challenging. Fortunately, recent medical advances, particularly chest computed tomography (CT), facilitate visualizing and quantifying mucus in patients with lung diseases. Our goal is to initially assess mucus plugging in a diverse group of Canadians without lung disease and then compare these findings to those with asthma, COPD, and chronic cough. The investigators will recruit 100 healthy volunteers for comprehensive clinical and research evaluations, including sputum analyses, breathing tests, quality of life assessments, cough monitoring, and CT scans. In addition, testing will be conducted twice, two years apart, in 240 adult and 50 pediatric participants. This approach will enable the investigators to understand the burden of mucus and how it changes over time, explore proteins or chemicals in mucus that predict mucus persistence, and identify biomarkers that can help guide physicians to prescribe targeted treatments that might work better than others. The CANMuc team's findings will guide strategies for identifying and treating mucus plugging, inform policymakers, and share knowledge with Canadians living with asthma, COPD, and chronic cough.",[65,66,27],"Asthma","Chronic Obstructive Pulmonary Disease (COPD)",[68,69,27,66],"mucus occlusions","asthma","RECRUITING","2026-01-05",{"date":73,"type":42},"2026-01-07",{"date":75,"type":42},"2025-12-11",{"date":77,"type":21},"2028-04",{"name":79,"class":49},"McMaster University",6,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":87,"maxAge":17,"enrollmentInfo":88,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":90,"conditions":91,"keywords":92,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100616517","wenjuanxing-based-multidimensional-etiologic-screening-and-clinical-validation-of-chronic-cough-in-children-100616517","NCT07306637","Wenjuanxing-Based Multidimensional Etiologic Screening and Clinical Validation of Chronic Cough in Children","Inclusion CInclusion Criteria:\n\n1. Children aged 3 to 18 years, any sex.\n2. Presenting for medical care due to cough lasting ≥2 weeks.\n3. No fever within the past 2 weeks.\n4. Caregiver is willing to complete the Wenjuanxing questionnaire and agree to follow-up.\n\nExclusion Criteria:\n\n1. Presence of congenital airway malformations, chronic lung disease, or severe immunodeficiency.\n2. Recent participation in other interventional clinical research.\n3. Unable to complete follow-up as required.","3 Years",{"count":89,"type":21},400,"Chronic cough is a common and burdensome condition in children, with complex and overlapping etiologies that often lead to delayed diagnosis, misdiagnosis, and inappropriate treatment. This prospective, controlled, observational study aims to develop and clinically validate a Wenjuanxing-based, parent-reported, multidimensional etiologic screening questionnaire for pediatric chronic cough. Children aged 3-18 years presenting with cough lasting ≥2 weeks will be enrolled in a tertiary pediatric respiratory clinic and allocated to either a routine-care group or a questionnaire-assisted group. All caregivers will complete the standardized electronic questionnaire, which generates an automated preliminary etiologic suggestion based on symptom patterns, triggers, and associated features. Diagnostic accuracy, treatment effectiveness, and symptom resolution will be evaluated through structured follow-up at two weeks. The primary outcome is the difference in diagnostic accuracy between physicians using routine assessment alone and those supported by the questionnaire. Secondary outcomes include treatment response and prevention of cough chronicity. This study seeks to provide evidence for a scalable, digital, and standardized screening tool to improve early etiologic identification and clinical decision-making in pediatric chronic cough.",[27],[93,36,94,95],"Pediatric","Etiologic Screening","Electronic Questionnaire","2025-12-14",{"date":98,"type":42},"2025-12-29",{"date":100,"type":21},"2026-01",{"date":102,"type":21},"2027-12",{"name":104,"class":49},"Shanghai Children's Medical Center",1,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":59,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":116,"conditions":117,"keywords":118,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":105},"100599552","phase-1-the-safety-feasibility-and-repeatability-of-inhaled-atp-cough-challenges-100599552","NCT07085975","The Safety, Feasibility, and Repeatability of Inhaled ATP Cough Challenges","Phase 1: Healthy individuals\n\nInclusion Criteria:\n\nEligible participants in Phase 1 will include healthy adults (≥18 years old) with:\n\n1. Normal spirometry; and\n2. No current or past medical history of chronic cough or other respiratory diseases.\n\nExclusion Criteria:\n\nWe will exclude healthy individuals meeting the following:\n\n(1) Are a current or former smoker with a \\>5 pack-year history and abstinence ≤6 months;\n\n1. Unable to perform acceptable and reproducible spirometry;\n2. Have unresolved symptoms of upper respiratory tract infection within 6 weeks prior to the first study visit;\n3. Have had a lower respiratory tract infection or pneumonia within 6 weeks prior to the first study visit;\n4. Presence of other primary pulmonary disorders, including pulmonary embolism, pulmonary hypertension, lung cancer, cystic fibrosis, radiologically-proven emphysema, severe bronchiectasis, or severe interstitial lung disease; or\n5. History of psychiatric illness, drug, or alcohol abuse that could interfere with participation in the study.\n6. History of clinically-significant cardiovascular disease, including coronary artery disease, aortic aneurysm, or stroke in the last 3 months;\n7. Those with serious medical conditions or those who are not on stable medication(s) for their condition(s);\n8. Those with immune system disorders, severe allergy, or on allergy-specific immunotherapy;\n9. Any other condition, that, in the opinion of the qualified investigator, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant;\n10. Pregnant or breastfeeding;\n11. Women of child-bearing potential who:\n\n    1. Do not agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of 3 months. Acceptable methods of birth control include oral contraceptives, hormone birth control patch, vaginal contraceptive ring, injectable contraceptives, or hormone implant, double-barrier method, intrauterine devices, non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s), vasectomy of partner at least 6 months prior to screening. Females who are not of child-bearing potential will be defined as females who have undergone a sterilization procedure (e.g., hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening.\n\nPhase 2: Patients with RCC\u002FUCC and mild-steroid naïve asthma\n\nInclusion Criteria:\n\nEligible participants will include adults (≥18 years old) with:\n\n1. RCC\u002FUCC for \\>1 year, demonstrated by a normal chest radiograph and no airflow obstruction (FEV1\u002FFVC\\>0.7\u002FLLN) with either:\n\n   1. Insufficient improvement in cough despite treatment targeting any underlying condition(s) contributing to the cough (RCC); or\n   2. Cough for which an underlying cause has not been determined despite thorough investigation (UCC).\n2. Mild steroid-naïve asthma who demonstrate evidence of a positive screening methacholine (PC20\\\u003C16 mg\u002FmL); symptoms of cough, shortness of breath, chest tightness, and wheeze, that, in the opinion of the qualified investigator, are well-controlled; and those have not used inhaled or oral corticosteroids for the past month.\n\nExclusion Criteria:\n\nCohort-specific exclusion criteria include the following:\n\nFor the RCC\u002FUCC cohort:\n\n(1) Current smoker or ex-smoker with ≥20 pack-year history and abstinence ≤6 months;\n\nFor the mild steroid-naïve asthma cohort:\n\n1. Current smoker or ex-smoker with ≥20 pack-year history and abstinence ≤6 months;\n2. History or exacerbation or uncontrolled symptoms within the last month prior to the first study visit; and\n3. Use of inhaled or oral corticosteroids within the last month prior to the first study visit.\n\nWe will exclude participants meeting any of the following criteria from the study:\n\n1. Unable to perform acceptable and reproducible spirometry;\n2. Unresolved symptoms of upper respiratory tract infection within 6 weeks prior to the first study visit;\n3. Lower respiratory tract infection or pneumonia within 6 weeks prior to the first study visit;\n4. Presence of other primary pulmonary disorders, including pulmonary embolism, pulmonary hypertension, lung cancer, cystic fibrosis, radiologically-proven emphysema, severe bronchiectasis, or severe interstitial lung disease;\n5. History of psychiatric illness, drug, or alcohol abuse that could interfere with participation in the study;\n6. History of clinically-significant cardiovascular disease, including coronary artery disease, aortic aneurysm, or stroke in the last 3 months;\n7. Those with serious medical conditions or those who are not on stable medication(s) for their condition(s);\n8. Those with immune system disorders, severe allergy, or on allergy-specific immunotherapy;\n9. Any other condition, that, in the opinion of the qualified investigator, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant;\n10. Pregnant or breastfeeding;\n11. Female participants of child-bearing potential who:\n\n    1. Do not agree to use a medically approved method of birth control for the duration of the study;\n    2. Have not been using hormonal birth control for a minimum of 3 months prior to screening.",{"count":113,"type":21},33,[115],"PHASE1","The inhalation of adenosine 5'-triphosphate (ATP) to evoke cough (ATP cough challenge) is becoming increasingly used as a tool to measure cough hypersensitivity in patients with chronic cough. However, the safety, feasibility, and repeatability of this procedure is not widely known. In this study, we will perform ATP cough challenges in healthy individuals and in patients with mild asthma and chronic cough to better understand the safety, feasibility, and repeatability of these challenges. Such information will guide the future conduct of ATP cough challenges to measure cough hypersensitivity and identify patients who may better respond to ATP-blocking therapies.",[27,65],[119,36,69,31],"adenosine triphosphate","2025-08-28",{"date":122,"type":42},"2025-08-29",{"date":124,"type":42},"2025-08-05",{"date":126,"type":21},"2026-10-01",{"name":79,"class":49},{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":139,"conditions":140,"keywords":143,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":105},"100564872","early-phase-1-efficacy-of-intramuscular-steroid-injection-for-chronic-cough-100564872","NCT06634823","Efficacy of Intramuscular Steroid Injection for Chronic Cough.","Prospective Placebo-Controlled Trial of Intramuscular Steroid Administration for the Treatment of Unexplained Chronic Cough","Inclusion Criteria:\n\n* History consistent with chronic unexplained or refractory cough\n* Age ≥ 18\n\nExclusion Criteria:\n\n* Current smokers\n* Uncontrolled diabetes (A1c\\>7%)\n* Patients on ACE inhibitors or Angiotensin II receptor blockers (ARBs)\n* Abnormal pulmonary function testing (PFTs) since start of the cough\n* Patients with uncontrolled obstructive sleep apnea\n* Abnormal chest X-ray within past 6 months\n* Uncontrolled reflux\n* Prior superior laryngeal nerve injection\n* Current neuromodulating medication use for chronic cough\\*",{"count":136,"type":21},40,[138],"EARLY_PHASE1","The primary goal of this study is to test the hypothesis that injecting steroid intramuscularly is an effective treatment for unexplained chronic cough. This will be achieved through the design of a prospective, placebo-controlled, single-blind, randomized clinical trial in which one group of patients will undergo a steroid injection into the deltoid muscle and the second group will undergo a placebo injection into the deltoid muscle. Data to determine if a clinically significant difference exists between the outcomes of the two groups will be measured by a dichotomous yes\u002Fno response to improvement, the Leicester Cough Questionnaire, and a visual analogue scale for symptom severity. This will provide the answer to the general question of whether or not the intramuscular injections are clinically effective for patients with unexplained chronic cough. Furthermore, any adverse reactions will be thoroughly documented. If this hypothesized treatment is proven effective, this can greatly improve the care of chronic cough patients by allowing for an evidence-based treatment option and a treatment option that may improve access to care. While the superior laryngeal nerve (SLN) injection is typically performed by fellowship trained laryngologists, intramuscular injections could be more widely utilized by general otolaryngologists or providers in other fields of medicine.",[27,141,142],"Laryngeal Disease","Coughing",[144,145,146,147],"Throat","Chronic cough","Neurogenic cough","Unexplained cough","2025-07-09",{"date":150,"type":42},"2025-07-14",{"date":152,"type":42},"2024-12-02",{"date":154,"type":21},"2026-06-30",{"name":156,"class":49},"Medical University of South Carolina",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":59,"sex":16,"minAge":17,"maxAge":164,"enrollmentInfo":165,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":167,"conditions":168,"keywords":169,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":105},"100562244","investigating-the-role-of-atp-production-by-airway-epithelium-in-patients-with-refractory-and-unexplained-chronic-cough-rccucc-100562244","NCT06600646","Investigating the Role of ATP Production by Airway Epithelium in Patients With Refractory and Unexplained Chronic Cough (RCC\u002FUCC).","APEC","Inclusion Criteria for RCC\u002FUCC:\n\n* Patients with a history of RCC\u002FUCC.\n* Normal Chest X-ray in the last 5 years.\n* No Evidence of Airflow Obstruction (FEV1\u002FFVC ratio above LLN)\n* Cough Severity VAS ≥ 40 mm at screening.\n\nInclusion Criteria for Healthy Controls:\n\n* No history of chronic cough, asthma, COPD, or clinical history of bronchiectasis or interstitial lung disease\n* No current smokers or those with \\>10 pack year history.\n* No evidence of airflow obstruction ( FEV1\u002FFVC ratio above LLN).\n* Able to understand and give written informed consent.\n\nExclusion Criteria:\n\n* Participants who are currently established on treatment and their chronic cough is well controlled.\n* Unable to perform acceptable and reproducible spirometry.\n* Participants with a positive covid-19 test within 2 weeks of screening.\n* Current smoker or ex-smoker with ≥20 pack year smoking history and abstinence of ≤6 months\n* Symptoms of upper respiratory tract infection in the last 1 month which have not resolved\n* Lower respiratory tract infection or pneumonia in the last 1 month\n* Asthma exacerbation in the previous month requiring an increase or start of an inhaled corticosteroid (ICS) or oral corticosteroid (OCS)\n* Significant other primary pulmonary disorders in particular; pulmonary embolism, pulmonary hypertension, lung cancer, cystic fibrosis, significant radiologically proven emphysema, interstitial lung disease or bronchiectasis.\n* History of psychiatric illness, drug or alcohol abuse which may interfere in the participation of the trial.\n* Allergy or intolerance to sedation medication including fentanyl and midazolam, or a history of complications during procedural sedation\n* Severe coagulopathy, bleeding disorder, or medical need for anti- coagulation that would increase the risk of endobronchial biopsy as determined by the investigator","80 Years",{"count":166,"type":21},30,"Chronic cough is a common troublesome symptom which has a global prevalence of approximately 10%, but with wide variations across continents. Patients with refractory and unexplained chronic cough (RCC\u002FUCC) often exhibit dysregulated vagal pathways, necessitating a neuronal biomarker for targeted treatment. ATP, involved in the ATP\u002FP2X3 pathway, may serve as a potential biomarker due to its role in the cough reflex. The study aims to discover if ATP production by the airway epithelium is greater in RCC\u002FUCC patients compared with healthy controls, if the epithelium is a source of ATP, whether gene and protein expression related to ATP production differs between these groups and whether ATP release is triggered by mechanical and chemical stimulation. Additionally, the study seeks to determine if biomarker gene expression signatures can differentiate RCC\u002FUCC patients from healthy controls.",[27],[36,170,171],"ATP","airway nerves","2025-05-05",{"date":174,"type":42},"2025-05-08",{"date":176,"type":42},"2024-11-22",{"date":178,"type":21},"2025-12-31",{"name":79,"class":49},{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":59,"sex":16,"minAge":17,"maxAge":164,"enrollmentInfo":187,"targetDuration":189,"studyType":62,"phases":4,"briefSummary":190,"conditions":191,"keywords":192,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":105},"100582365","china-chronic-cough-registry-a-multicenter-prospective-observational-study-100582365","NCT06862362","China Chronic Cough Registry: a Multicenter, Prospective, Observational Study","China Chronic Cough Cohort Study","Inclusion Criteria:\n\n* Is over 18 years old\n* Cough as the sole or main symptom\n* Has cough lasting more than 8 weeks\n* No obvious findings of Chest X-ray \u002F Chest CT\n* Has no other evident diagnoses (e.g. IPF, NCFB, COPD, bronchiectasis, lung cancer)\n* Has given signed consent for inclusion in the study\n\nExclusion Criteria:\n\n\\-",{"count":188,"type":21},6000,"2 Years","The aim is to establish a national clinical database and biobanks for chronic coughers. Through real-world chronic cough case registry and follow-up studies, we will explore the clinical phenotypes and molecular subtypes of chronic cough.",[27],[36,193,194,195],"registry","clinical data","biosample","2025-03-03",{"date":198,"type":42},"2025-03-06",{"date":200,"type":21},"2025-05-01",{"date":202,"type":21},"2028-12-31",{"name":204,"class":49},"The First Affiliated Hospital of Guangzhou Medical University",{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":59,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":213,"conditions":214,"keywords":215,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":105},"100574968","impact-of-chronic-cough-on-activities-of-daily-living-and-response-to-acute-high-intensity-exercise-100574968","NCT06766175","Impact of Chronic Cough on Activities of Daily Living and Response to Acute High-intensity Exercise","Inclusion Criteria:\n\n* Age \\>18 years\n* Chronic cough as per European Respiratory Society definition (\\>8 weeks duration)\n* High symptom burden (i.e., cough visual analogue scale \\>40 mm at pre-study screening)\n* Chest radiograph or CT within 3 years of the screening visit with no abnormalities considered to contribute to chronic cough\n\nExclusion Criteria:\n\n* Smokers or individuals who gave up smoking within 12 months\n* Smoking history \\>20 pack-years\n* Long-COVID or post-COVID syndrome (defined as symptoms lasting over 12-weeks in duration)\n* Recent exacerbation of cough within 4 weeks of inclusion\n* Respiratory tract infection within 4 weeks of inclusion\n* Currently taking any of the following medications:\n\n  * ACE inhibitors and within 3 months of inclusion\n  * Antitussives (opioids, pregabalin, gabapentin, amitriptyline, nortriptyline, or over the-counter medications) within 2 weeks of inclusion\n  * Medical treatments for gastro-oesophageal reflux disease (GORD), eosinophilic bronchitis or other cough related conditions, initiated or changed (i.e., not in a stable regimen) for 4 weeks prior to inclusion\n* Medical history of asthma or exercise-induced bronchoconstriction (EIB), COPD, or chronic bronchitis in the judgement of the investigator\n* Medical conditions\u002Fhistory or other circumstances which, in the judgement of the investigators, could increase the risk of adverse events or bias the study results",{"count":212,"type":21},129,"Chronic cough is a common and debilitating condition that affects up to 10% of the global population. The health impact of chronic cough is multifaceted and manifests both physical and psychological symptoms including syncope, chest pain, lethargy, depression and anxiety. It is now also recognised that chronic cough often leads to social isolation and may impact an individual's ability or confidence to undertake routine daily tasks \u002F lead an active lifestyle.\n\nThe primary aim of this study is therefore to characterise the impact of unexplained chronic cough on the ability to undertake daily activities - i.e., determine whether individuals with chronic cough exhibit impaired levels of physical activity during usual daily living when compared with healthy age, gender and BMI matched controls. A secondary aim is to assess the short-term impact of high-intensity exercise on cough (i.e., determine whether an acute bout of exercise alters cough frequency and\u002For severity).",[27],[216,217,218,219],"Cough","Physical activity","Exercise","Physiology","2025-01-03",{"date":222,"type":42},"2025-01-09",{"date":224,"type":42},"2024-12-01",{"date":226,"type":21},"2026-12",{"name":228,"class":49},"University of Leeds"]